Kuno van der Post Ph.D
OmniComm Systems, Inc.
Fort Lauderdale, FL, July 31, 2012 – OmniComm Systems, Inc., one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, today announced that its eClinical Suite of applications has been licensed by Cytochroma Inc., for 2 Phase III studies. Both of these 30 site, Phase III studies are evaluating the efficacy and safety of CTAP101 Capsules to treat secondary hyperparathyroidism in subjects with stage 3 Chronic Kidney Disease (CKD) and vitamin D insufficiency.
“We are pleased with the partnership we have formed with OmniComm as our primary eClinical vendor for these crucial studies,” said Joel Melnick, Vice President, Clinical Research and Development. “The integrated suite of EDC, CTMS, and Safety has streamlined our processes and allows us to focus on executing the trials.”
OmniComm’s eClinical Suite, including the EDC, CTMS, Safety, and Coding solutions, will be used to collect, process, and analyze patient data and adverse events throughout the life of each trial. Cytochroma had successfully utilized OmniComm’s eClinical Suite for 2 previous studies over the last couple of years.
“We are very excited to be working again with this specialty pharmaceutical company on these important studies,” commented Stephen Johnson, OmniComm’s President & COO. “We appreciate their ongoing trust in us and will continue to deliver superior products and services to them as they strive to bring life-changing drugs to market.”
OmniComm’s commitment to innovation and continual product improvement has fueled OmniComm’s rapid growth over the last several years. The eClinical Suite’s strong functional capabilities, combined with OmniComm’s outstanding customer service, has been increasingly well received by the clinical community, making OmniComm the preferred choice for Electronic Data Capture and eClinical solutions around the world.
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
About Cytochroma Inc.
Cytochroma Inc. is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients. Cytochroma’s expertise in vitamin D chemistry, biochemistry, metabolism and physiology, combined with its experience in bringing vitamin D-based therapeutics to market uniquely positions the Company to improve the lives of CKD patients suffering from diseases related to vitamin D insufficiency and SHPT.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.